MK-677 at 10mg: what the fitness crowd gets wrong
Quick answer
MK-677 (ibutamoren) is an oral ghrelin receptor agonist that stimulates pulsatile growth hormone release and elevates IGF-1, with documented effects on sleep architecture and lean body mass in clinical trials conducted primarily in elderly or GH-deficient populations. The creator's claims about sleep improvement and recovery have biological plausibility supported by published data, but their framing omits clinically significant adverse effects including insulin resistance, fasting hyperglycemia, and fat mass accumulation documented across multiple trials. MK-677 is not FDA-approved and its safety and efficacy in healthy adults pursuing body composition goals has not been established in adequately powered randomized controlled trials.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @truediagofit actually say?
The creator claims 10mg of MK-677 produces rapid, noticeable changes: deep sleep "within days," faster recovery, reduced joint pain, fuller muscles, and steady weight gain, all without severe bloating or uncontrollable hunger. Their framing is that this dose is a "subtle mass builder" that keeps growth "sustainable."
It is a relatively measured pitch by bodybuilding TikTok standards. There is no wild transformation promise, no before-and-after miracle, and no claim of pharmaceutical-grade results. The tone is conversational and the timeline is vague enough to avoid outright falsifiability. That does not mean it is accurate, but it is worth noting they did not go off the deep end.
Does the science back this up?
Partially, but the picture is messier than the video lets on. MK-677 (ibutamoren) is a ghrelin receptor agonist that stimulates growth hormone secretion and raises IGF-1. That much is established. The sleep and recovery claims have some legitimate support. The "subtle mass builder" framing glosses over real metabolic risks.
On sleep: a 1997 study by Copinschi et al. in Sleep found that MK-677 increased REM sleep and sleep quality in young adults, which aligns with the "deep, dream-filled" description. On IGF-1 and tissue effects: Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed sustained IGF-1 elevation over two years in elderly subjects. The recovery and joint relief claims are biologically plausible given IGF-1's role in connective tissue, but there is no clean clinical trial proving this at 10mg specifically in healthy adults. On hunger: the creator actually undersells this. Ghrelin receptor activation reliably increases appetite, and several subjects in trials reported it as a significant side effect, not a mild "steady craving."
What did they get wrong (or right)?
They got the sleep effect roughly right. They got the appetite effect wrong by minimizing it. They missed the risks almost entirely.
Calling appetite changes "not insane binge hunger, but steady constant cravings" is optimistic. In the Svensson et al. (1998, Journal of Clinical Endocrinology and Metabolism) trial, increased appetite was one of the most reported side effects and correlated with meaningful fat mass increases alongside lean mass gains. The "weight climbing slow but clean" line deserves scrutiny. MK-677 does not produce clean lean gains the way the creator implies. Fat mass often increases alongside muscle fullness, particularly at higher or sustained doses.
More importantly, the video says nothing about insulin resistance. Multiple studies, including Nass et al. (2008, Annals of Internal Medicine), documented increased fasting glucose and worsening insulin sensitivity in subjects on MK-677. For anyone with pre-diabetic markers, this is not a minor footnote. Water retention was also underplayed. Bloating is a common complaint, and describing MK-677 as something that avoids it does not match user data or trial adverse event profiles.
What should you actually know?
MK-677 is not approved by the FDA for any indication. It is not a peptide in the strict pharmacological sense but a small molecule secretagogue. It is not legal to sell as a supplement, and its use without medical supervision carries real metabolic risks that a 45-second TikTok will not cover.
The legitimate research on MK-677 exists mostly in elderly or growth hormone-deficient populations, not healthy young adults seeking body composition changes. Extrapolating those findings to a 25-year-old lifter is a meaningful scientific stretch. The Copinschi sleep data is real, but it was collected in a controlled clinical setting, not from someone self-dosing based on a social media video.
If you are interested in growth hormone optimization, that is a conversation worth having with a licensed clinician who can assess your IGF-1 baseline, metabolic markers, and actual health goals. A TikTok caption with the hashtag "gear" is not a protocol.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For MK-677 at 10mg: what the fitness crowd gets wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Ipamorelin, the first selective growth hormone secretagogue
Background source for ipamorelin selectivity and GH-secretagogue mechanism.
PubMed
The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation
Preclinical context that should not be overstated as consumer clinical evidence.
PubMed
GLP-1 receptor agonists versus metformin in PCOS: a systematic review and meta-analysis
Used for PCOS pages comparing metabolic and weight-management approaches.
PubMed
The efficacy and safety of GLP-1 agonists in PCOS women living with obesity
Supports PCOS, obesity, and hormonal-regulation context.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
MK-677 at 10mg: what the fitness crowd gets wrong is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
Compare providers, services and access requirements in the directory before contacting a suitable care team.
Helpful context before the funnel
Claim verdict
The useful answer behind this video
Claim being checked
MK-677 (ibutamoren) is an oral ghrelin receptor agonist that stimulates pulsatile growth hormone release and elevates IGF-1, with documented effects on sleep architecture and lean body mass in clinical trials conducted primarily in elderly or GH-deficient populations.
FormBlends verdict
MK-677 (ibutamoren) is an oral ghrelin receptor agonist that stimulates pulsatile growth hormone release and elevates IGF-1, with documented effects on sleep architecture and lean body mass in clinical trials conducted primarily in elderly or GH-deficient populations. The creator's claims about sleep improvement and recovery have biological plausibility supported by published data, but their framing omits clinically significant adverse effects including insulin resistance, fasting hyperglycemia, and fat mass accumulation documented across multiple trials. MK-677 is not FDA-approved and its safety and efficacy in healthy adults pursuing body composition goals has not been established in adequately powered randomized controlled trials.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- MK-677 (ibutamoren) is an oral ghrelin receptor agonist that stimulates pulsatile growth hormone release and elevates IGF-1, with documented effects on sleep architecture and lean body mass in clinical trials conducted primarily in elderly or GH-deficient populations. The creator's claims about sleep improvement and recovery have biological plausibility supported by published data, but their framing omits clinically significant adverse effects including insulin resistance, fasting hyperglycemia, and fat mass accumulation documented across multiple trials. MK-677 is not FDA-approved and its safety and efficacy in healthy adults pursuing body composition goals has not been established in adequately powered randomized controlled trials.
- Copinschi et al. (1997, Sleep) confirmed MK-677 increases REM sleep in young adults, so the sleep claim has real support, but it came from a controlled clinical trial, not self-directed dosing.
- MK-677 is not FDA-approved for any use and is classified as an investigational drug, meaning purchasing and using it outside of a clinical context carries legal and health risks.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Copinschi et al. (1997, Sleep) confirmed MK-677 increases REM sleep in young adults, so the sleep claim has real support, but it came from a controlled clinical trial, not self-directed dosing.
- MK-677 is not FDA-approved for any use and is classified as an investigational drug, meaning purchasing and using it outside of a clinical context carries legal and health risks.
- Nass et al. (2008, Annals of Internal Medicine) documented increased fasting glucose and insulin resistance in MK-677 users, a side effect the video does not mention at all.
- Studies showing lean mass benefits, including Murphy et al. (1998, JCEM), were conducted in elderly or growth hormone-deficient patients, not healthy young adults, making direct extrapolation unreliable.
- Appetite increase from MK-677 is a pharmacologically predictable effect of ghrelin receptor activation and was significant enough in trials to contribute to fat mass gain alongside muscle fullness.
- Water retention is a commonly reported adverse effect in both trial data and clinical practice, directly contradicting the creator's claim of minimal bloating.
- Anyone considering MK-677 for recovery or body composition should discuss IGF-1 baseline levels, fasting glucose, and metabolic health with a licensed clinician before use.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Diago Fit · TikTok creator
45.9K views on this video
This is what 10mgs of MK-677 will do... #diagofit #gymtok #gear #mk677
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Diago Fit, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.